Ozmosi | Nelivaptan Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Nelivaptan

Alternative Names: nelivaptan, ssr149415
Clinical Status: Active
Latest Update: 2025-08-05
Latest Update Note: News Article

Product Description

Mechanisms of Action: V1b Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nelivaptan

Countries in Clinic: Bulgaria, Estonia, Germany, Lithuania, Poland, Slovakia, Spain

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Depressive Disorder, Major

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

BH-200-03

P2

Completed

Depressive Disorder, Major

2025-04-08

2025-05-02

Treatments